Johnson & Johnson (JNJ)
Johnson & Johnson proposes $5.5B settlement to resolve remaining talc litigation
Johnson & Johnson (NYSE:JNJ) has reached an agreement to resolve tens of thousands of lawsuits in the US alleging that its talc-based products, including its baby powder, caused ovarian cancer, with the company committing up to $5.5 billion to settle the remaining claims. The proposed resolution would bring an end to a long-running legal battle that has involved around 76,000 ovarian talc claims and weighed on the healthcare company for more than a decade.
Johnson & Johnson Stock Hits Record High on $5.5 Billion Settlement
Johnson & Johnson (NYSE:JNJ) was last seen up 2.4% at $272.31, and earlier hit a record high of $274.90, after the healthcare giant agreed to pay $5.5 billion to settle roughly 76,000 remaining U.S. lawsuits alleging its talc products caused ovarian cancer.
J&J offers $5.5bn to settle baby powder lawsuits
Johnson & Johnson (J&J) has offered to pay $5.5bn (£4.13bn) to resolve tens of thousands of lawsuits in the US alleging its talcum powder caused ovarian cancer.
ETFs to Buy Post JNJ's Q2 Earnings Beat & Bullish 2026 Outlook
Johnson & Johnson's Q2 beat and strong pharma momentum are raising interest in healthcare ETFs with sizable exposure to the company.
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.
Johnson & Johnson's robotic surgery device gets US FDA marketing authorization
Johnson & Johnson said on Wednesday the U.S. Food and Drug Administration had granted marketing authorization for its robotic surgery device, clearing the way for the healthcare conglomerate to enter the soft-tissue robotic surgery market.
Should You Buy, Sell or Hold J&J's Stock Post a Robust Q2 Performance?
Johnson & Johnson JNJ announced robust second-quarter 2026 results on July 15, beating estimates for both earnings and sales. While earnings rose 4.7%, sales rose 6.6% from the year-ago period.
Why Johnson & Johnson Is a Stock You Can Own Forever
Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) is a stock built to be owned for decades, not traded, because its combination of an AAA-tier balance sheet, a 64-consecutive year dividend growth streak and a diversified healthcare franchise across pharmaceuticals and medical devices is engineered to compound quietly through every market cycle.
3 Dividend Stocks That Have Survived Every Market Crash in July
July tests investor conviction. From the 2011 debt-ceiling standoff to the 2022 inflation shock, summer volatility has separated durable businesses from cyclical hopefuls.
J&J Stock Falls Despite Strong Q2 Beat & Higher 2026 View: Here's Why
JNJ beats Q2 estimates and raises 2026 guidance, but shares fall as MedTech misses expectations. Find out what weighed on the unit and what's next.
I Was Wrong About Johnson & Johnson: Upgrading To Hold (Rating Upgrade)
Johnson & Johnson posted strong Q2 earnings. Sales of its NMDA receptor antagonist, called Spravato, for the treatment of depression, rose 41.1% year-on-year to $584 million in Q2. Also, J&J raised its 2026 adjusted diluted EPS guidance from $11.45-$11.65 to $11.6-$11.75.
Johnson & Johnson Raises 2026 Outlook After Q2 Earnings Beat
Johnson & Johnson raises its 2026 outlook after Q2 earnings and revenues beat estimates, driven by Innovative Medicine strength and pipeline momentum.
